

Are there clinical and subclinical/pathological forms of Paget's disease of the breast?

Supplementary material

S.Table 1	Clinical-radiological variables.....	2
S.Table 2	Relation between pathologic and prognostic TNM.....	4
S.Table 3	Comparison between invasive disease and molecular subtype	5
S.Table 4	Treatment carried out and evolution related to PDB	6
S.Table 5	Cancer-specific survival as a function of treatment type	7
S.Figure 1	Clinical presentations of PDB	8
S.Figure 2	Survival: (a) Overall; (b) cancer specific survival	9
S.Figure 3	Cancer-specific survival (a) Clinical PDB; (b) pathological evaluation; (c) clinical stage TNM (d) prognostic stage TNM; (e) molecular subtype; (f) anti-HER therapy.....	10

Supplementary Table 1. Clinical-radiological variables

Variable	Category	PDB clinical		Total	p
		Present	Absent		
Clinical presentation					
Eczema*	Absent	15	35	50 (58.8)	<0.001
	Present	35	0	35 (41.2)	
Bleeding	Absent	40	32	72 (84.7)	0.222
	Present	10	3	13 (15.3)	
Tumor	Absent	36	8	44 (51.8)	<0.001
	Present	14	27	41 (48.2)	
Physical exam					
Eczema*	Absent	20	35	55 (64.7)	< 0.001
	Present	30	0	30 (35.3)	
Ulceration*	Absent	26	35	61 (71.8)	< 0.001
	Present	24	0	24 (28.2)	
Peeling*	Absent	26	35	61 (7.8)	< 0.001
	Present	24	0	24 (28.2)	
Tumor	Absent	30	7	37 (43.5)	< 0.001
	Present	20	28	48 (56.5)	
Mammography					
Normal	Absent	37	27	64 (87.7)	0.303
	Present	7	2	9(12.3)	
Skin thickening	Absent	34	28	62 (84.9)	0.041
	Present	10	1	11 (15.1)	
Malignant calcification	Absent	21	9	30 (41.1)	0.224
	Present	23	20	43 (58.9)	
Nodulation	Absent	29	17	46 (63.0)	0.622

	Present	15	12	27 (37.0)	
Asymmetry	Absent	35	23	58 (79.5)	1.000
	Present	9	6	15 (20.5)	
Architectural	Absent	44	27	71 (97.3)	0.154
distortion	Present	0	2	2 (2.7)	
Ultrasonography					
Microcalcification	Absent	43	29	72 (91.1)	0.133
	Present	2	5	7 (8.9)	
Nodulation	Absent	16	6	22 (27.8)	0.127
	Present	29	28	57 (72.2)	
NAC thickening	Absent	37	33	70 (88.6)	0.007
	Present	8	1	9 (11.4)	

*Criteria used in the definition of clinical PDB; NAC - Nipple Areolar Complex

Supplementary Table 2. Relation between pathologic and prognostic TNM ($p < 0,001$)

Prog Clinic	0	I	II	III	IV	All
0	23	0	0	0	0	23 (27,1%)
I	0	19	0	1	0	20 (23,5%)
II	0	4	13	0	0	17 (20,0%)
III	0	1	4	19	0	24 (28,2%)
IV	0	0	0	0	1	1 (1,2%)
All	23 (27,1%)	24 (28,2%)	17 (20,0%)	20 (23,5%)	1 (1,2%)	85 (100,0%)

Prog= prognostic TNM; Clinic= clinical TNM

Supplementary Table 3. Comparison between invasive disease and molecular subtype.
(p=0.018)

	CDIS	Invasive carcinoma	Total
Luminal B Her -	0	12 (19.4%)	12 (14.5%)
Luminal B Her +	2 (9.5%)	17 (27.4%)	19 (22.9%)
Her2 +	16 (76.2%)	26 (41.9%)	42 (50.6%)
Triple negative	3 (14.3%)	7 (11.3%)	10 (12.0%)
Total	21 (25.3%)	62 (74.7%)	83 (100.0%)

* Two cases without information excluded

Supplementary Table 4. Treatment carried out and evolution related to PDB

Variable	Category	Clinical PDB			p
		Present	Absent	Total	
Treatment					
Breast	Mastectomy	30	32	62 (72,9%)	< 0,001
Surgery	BCS	20	3	23 (27,1%)	
Initial OS	Present	33	22	55 (64,7)	0,821
	Absent	17	13	30 (35,3%)	
Axillary	AL	17	15	32 (37,6%)	0,97
	Surgery	SNB	27	20	
	Absent	6	0	6 (7,1%)	
Chemotherapy*	Absent	7	9	16 (25,0%)	0,774
	Present	25	23	48 (75,0)	
Radiotherapy**	Absent	17	17	34 (40,0%)	0,187
	Present	33	18	51 (60,0%)	
Her2 Therapy [#]	Absent	6	7	13 (30,2%)	0,509
	Present	18	12	30 (69,8%)	
Follow-up					
Local recurrence	Absent	47	34	81 (95,3%)	0,640
	Present	3	1	4 (4,7%)	
Final status	LC	41	28	69 (81,2%)	0,296
	LR	0	1	1 (1,2%)	
	CRD	4	5	9 (10,6%)	
	DAD	5	1	6 (7,1%)	

PDB= Paget Disease of the Breast; BCS= Breast Conservative Surgery; SNB= Sentinel Node of the Breast; AL: axillary lymphadenectomy; OS= Oncoplastic Surgery; LWC= Live without cancer; LWR= life with cancer recurrence; CRD= Cancer related death; DAD= Death associated to other disease


Supplementary Table 5. Cancer-specific survival as a function of treatment type

Variable	Category	CSS		p
		60 months	120 months	
Breast	Mastectomy	89,6	79,9	0,251
surgery	BCS	100	91,7	
Initial OS	Present	91,3	84,0	0,785
	Absent	93,3	81,6	
Axillary	AL	86,1	74,8	0,227
surgery	SNB	96,3	91,2	
	Absent	100	80,0	
Chemotherapy*	Absent	90,9	90,9	0,355
	Present	89,3	75,0	
Radiotherapy**	Absent	92,6	92,6	0,243
	Present	92,2	76,9	
Her2 Therapy [#]	Her+ with TZM	91,3	91,3	0,500
	Her+ without TZM	91,7	83,3	


CSS - Cancer-Specific Survival; BCS= Breast Conservative Surgery; SNB= Sentinel Node of the Breast; AL: axillary lymphadenectomy; OS= Oncoplastic Surgery; TZM= Trastuzumab; *Patients with invasive disease; # Patients with invasive disease Her 2 +



Supplementary Figure 1. Clinical presentations of Paget's disease of the breast



Supplementary Figure 2. Survival: (a) Overall; (b) cancer-specific survival



Supplementary Figure 3. Cancer-specific survival (a) Clinical PDB; (b) pathological evaluation; (c) clinical stage TNM (d) prognostic stage TNM; (e) molecular subtype; (f) anti-HER therapy